In human fetal pituitary cultures, lanreotide's GH suppression EC50 was 2.30 nM, versus 0.05-0.09 nM for enhanced-SSTR2-affinity compounds and 0.19 nM for SRIF.
In plain wordsIn human fetal pituitary cells, lanreotide required a higher concentration for half-maximal GH suppression than enhanced-SSTR2-affinity compounds or SRIF.
- Peptide
- Lanreotide
- Outcome
- Not applicableGH suppression EC50
- Study
humann: not reported in source
Primary human fetal pituitary cultures- Comparator
- Compounds with enhanced SSTR2 affinity and SRIF
- Outcome group
- Growth hormone and IGF-1 · Endocrine and hormones
- Studied dose
- Dose not stated
Measurements
- EC50
- 2.3 nM
- GH suppression
Source sentences
and compounds with enhanced affinity for SSTR2 were more potent (EC50 for GH suppression, 0.05-0.09 nM) than Lanreotide (EC50, 2.30 nM) and SRIF (EC50, 0.19 nM).
1 context sentence(design, population, supporting numbers)
We therefore tested SSTR subtype-specific SRIF analogs in primary human fetal pituitary cultures (23-25-wk gestation) to elucidate their role in regulating human pituitary function.